NSE filing, NSE: VAISHALI. Summary written from the filing by ALFA Finder's alert engine.
Vaishali Pharma Ltd: key numbers
- Share price
- ₹6.81
- Market cap
- ₹91.94 Cr
- Revenue (annual)
- ₹108.8 Cr
- Net profit (annual)
- ₹4.16 Cr
- P/E (TTM)
- 20.8×Sector 37.9×
- Promoter holding
- 31.61%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaishali Pharma Ltd
All →Vaishali Pharma Board Meeting Date
Vaishali Pharma has scheduled an audit committee meeting for 5 November 2026. Proposed agenda includes a fund raise via preferential issue and an increase in authorised capital.
Vaishali Pharma Preferential Issue
NSE has approved the listing of 45,37,865 equity shares allotted on a preferential basis by Vaishali Pharma Ltd, effective from October 16, 2026.
Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited concluded its 19th Annual General Meeting on September 24, 2026, via video conferencing, transacting routine ordinary business matters.
Vaishali Pharma Capital Structure Change
Vaishali Pharma Ltd received listing approval from NSE for 45,37,865 equity shares issued on a preferential basis, subject to depository confirmation.
Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited will hold its 19th Annual General Meeting on September 24, 2026, through video conferencing to transact ordinary business.
Vaishali Pharma Management Change
Vaishali Pharma Limited announced the resignation of Mr. Bhaveshkumar Popatlal Upadhyay from the position of Non-Executive Independent Director, effective August 14, 2026.
Other management change announcements
All →Coforge Management Change
Coforge issued a postal ballot notice seeking shareholder approval to appoint Akhil Kumar Gupta as an Independent Director for five years. E-voting runs November 6 to December 5, 2026.
Ugro Capital Management Change
Ugro Capital's internal auditor Kavita Shedge resigned, effective 06-11-2026. Chandrakant Bhagwat was appointed Company Secretary and Compliance Officer, effective 01-12-2026.
Paras Healthcare Management Change
Paras Healthcare's board confirmed continuation of Mr. Kabir Kishin Thakur as Non-Executive Non-Independent Director under Regulation 17(1D), effective 5 November 2026. The outcome was reported after a board meeting held the same day.
Organic Coatings Management Change
Organic Coatings appointed Tejas Rajeshbhai Basrani as Chief Financial Officer, effective November 5, 2026. He brings over 15 years of finance, accounts and compliance experience.
Shriram Asset Management Company Management Change
Shriram Asset Management's board appointed Vikrant Gugnani as Executive Director (WTD) for 36 months from November 16, 2026. Two fund managers and a Principal Officer (PMS) were also appointed as senior management, effective November 6, 2026.
- Execution
- 36 months from 2026-11-16
Time Technoplast Management Change
Time Technoplast's board re-appointed Bharat Kumar Vageria as Executive Director and MD for 60 months from February 6, 2027. The filing reports a management reappointment only, with no financial figures.
- Execution
- 60 months from 2027-02-06